Poly(malic acid) bearing Doxorubicin and N-Acetyl Galactosamine as a site-specific prodrug for targeting hepatocellular carcinoma - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Journal of Biomaterials Science, Polymer Edition Année : 2017

Poly(malic acid) bearing Doxorubicin and N-Acetyl Galactosamine as a site-specific prodrug for targeting hepatocellular carcinoma

Résumé

In the past, several systems of drug delivery carriers have been designed with a high capacity to target specific cells and/or tissues and a reduced non-specific toxicity. In this context, we synthesized and characterized novel poly(malic acid) derivatives bearing Doxorubicin (Dox), Poly(ethylene glycol) (PEG) and/or N-Acetyl Galactosamine (NAcGal) for drug delivery. These poly(malic acid) derivatives were obtained by chemical modification of the carboxylic acid lateral groups of poly(malic acid) (PMLA). The resulting nanoplatforms were evaluated for their in vitro cytotoxicity using the human HepaRG hepatoma cell line. Results reveal that the PMLA nanoplatform modified with PEG and Dox has an IC50 of 936 nM corresponding to a Dox concentration of 47 nM, while the grafting of NAcGal onto the nanoplatform reduced the IC50 to 527 nM corresponding to a Dox concentration of 26 nM. The presence of the targeting moiety, NAcGal, thus improves the cellular toxicity of the Dox.
Fichier principal
Vignette du fichier
Poly(malic acid) bearing Doxorubicin-accepted.pdf (1.36 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01579649 , version 1 (31-08-2017)

Identifiants

Citer

Nivishna Venkatraj, M. J. Nanjan, Pascal Loyer, M. J. N. Chandrasekar, Sandrine Cammas-Marion. Poly(malic acid) bearing Doxorubicin and N-Acetyl Galactosamine as a site-specific prodrug for targeting hepatocellular carcinoma. Journal of Biomaterials Science, Polymer Edition, 2017, 28 (10-12), pp.1140-1157. ⟨10.1080/09205063.2017.1311294⟩. ⟨hal-01579649⟩
318 Consultations
255 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More